SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In addition, diabetic patients who were on sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, glucagon‐like peptide‐1 receptor antagonists, and insulin experienced a lower incidence of NAFLD.9